An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

PHASE3Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

October 26, 2027

Study Completion Date

December 7, 2027

Conditions

Generalized Myasthenia Gravis

Interventions

DRUG

Zilucoplan

Zilucoplan will be administered subcutaneously to pediatric study participants

Trial Locations (9)

Mg0015 50168, Chicago

Mg0015 50574, Denton

Mg0015 40144, Milan

Mg0015 40774, Katowice

Mg0015 40218, Warsaw

Mg0015 20104, Seoul

Mg0015 20220, Seoul

Mg0015 40735, Glasgow

Mg0015 40736, London

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY